Vaccination coverage of patients with type 2 diabetes mellitus: Challenging issues from an outpatient secondary care setting in Greece

Abstract

BackgroundIncreased morbidity/mortality due to vaccine preventable diseases (VPD) is encountered in type 2 diabetes (T2D) people. Aim of this study was to assess their vaccination coverage and describe trends possibly affecting compliance.MethodsInformation on vaccination coverage was retrieved from either documents or interview provided by patients, and/or their vaccination record card at a specialized outpatient diabetes center. The selection of the patients was arbitrary.ResultsAn increasing vaccination rate for influenza was observed from 2018 to 2020 among 372 participants. The vaccination coverage for S.pneumoniae was 67.2% (PCV13), 20.4% (PPSV23), 26.3% for herpes zoster in individuals ≥60 years, 1.9% for tetanus-diphtheria-pertussis and 1.1% for hepatitis B. A 10.2% of participants were found to be unvaccinated. Vaccination uptake for influenza and PCV13 was related to age, ≥3 comorbidities and long-term follow-up. T2D individuals consecutively vaccinated for influenza were 3.78 times more likely to be also vaccinated with PCV13.ConclusionsVaccination rates of patients with T2D show an increasing trend, especially for influenza and S. pneumoniae, although the one for S. pneumoniae was low. Older people seem more prone to vaccination, the one for herpes zoster was low with infected patients remaining unvaccinated while significantly low coverage was observed for other VPDs. The findings are important to improve effectiveness of preventative services.

Acceptability of Herpes Zoster Vaccination among Patients with Diabetes: A Cross-Sectional Study in Saudi Arabia

“…Although this rate is low, it is still higher than the rate of 4.5% in Riyadh and 18% in the whole Kingdom among patients with a history of HZ [ 4 , 21 ]. Our findings are consistent with the coverage rate in Greece, which was reported as 26.3% for the HZ vaccine among individuals with diabetes aged 60 years and older [ 22 ]. A wide range of variations have been noted in HZ vaccination coverage in different countries.…”

MAURIVAX: A Vaccination Campaign Project in a Hospital Environment for Patients Affected by Autoimmune Diseases and Adult Primary Immunodeficiencies

“…Thanks to the dedicated service we managed to create for these patients at risk, we have achieved a level of adherence to vaccinations after proper counseling in over 90% of cases; this rate, for the same vaccines performed, is above the rates of adherence to vaccines reported globally for cases of patients with ADs [20,21] or with other types of diseases at risk (diabetics [22,23], chronic lung diseases [24], splenectomized [25] patients).…”

Prevalence and awareness of Herpes Zoster Among Saudi Patients with Diabetes Mellitus, A Cross Sectional Study in Al-Ahsa, Saudi Arabia

“…The International Diabetes Federation (IDF) has observed that type 2 diabetes (T2D) is a rapidly growing global health concern that has reached epidemic proportions. Additionally, the number of new cases of T2D is projected to affect one out of every ten individuals worldwide by 2035 [10,11].Furthermore, according to the World Health Organization (WHO), Saudi Arabia ranks as the second-highest country in terms of diabetes prevalence in the Middle East and the seventh highest in the world [12]. A twenty-year audit study of herpes zoster (HZ) in the Asia-Pacific region identified immune senescence and immunosuppression as the principal risk factors for HZ [13].…”